Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Current Assets (2022 - 2025)

Historic Current Assets for Centessa Pharmaceuticals (CNTA) over the last 4 years, with Q3 2025 value amounting to $307.7 million.

  • Centessa Pharmaceuticals' Current Assets fell 4586.66% to $307.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $307.7 million, marking a year-over-year decrease of 4586.66%. This contributed to the annual value of $536.4 million for FY2024, which is 7023.89% up from last year.
  • According to the latest figures from Q3 2025, Centessa Pharmaceuticals' Current Assets is $307.7 million, which was down 4586.66% from $300.4 million recorded in Q2 2025.
  • Centessa Pharmaceuticals' Current Assets' 5-year high stood at $581.2 million during Q1 2022, with a 5-year trough of $284.5 million in Q1 2024.
  • Its 4-year average for Current Assets is $406.5 million, with a median of $355.5 million in 2024.
  • Per our database at Business Quant, Centessa Pharmaceuticals' Current Assets soared by 7096.07% in 2024 and then plummeted by 4586.66% in 2025.
  • Over the past 4 years, Centessa Pharmaceuticals' Current Assets (Quarter) stood at $437.7 million in 2022, then dropped by 28.02% to $315.1 million in 2023, then soared by 70.24% to $536.4 million in 2024, then plummeted by 42.64% to $307.7 million in 2025.
  • Its Current Assets stands at $307.7 million for Q3 2025, versus $300.4 million for Q2 2025 and $347.7 million for Q1 2025.